Home : FDA Drug Database : Activase : Newsfeeds

Activase - Newsfeeds

U.S. groups widen stroke treatment guidelines: A European clinical trial, published last fall in the New England Journal of Medicine, showed some patients who took privately held German drugmaker Boehringer Ingelheim's version of tPA, known as Actilyse or alteplase, were helped even 4 1/2 hours after ...
Prediction of two month modified Rankin Scale with an ordinal prediction model in patients with aneurysmal ...: © 2010 Risselada et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and ...
Intracerebral hemorrhage: lower doses of tPA safer: A Johns Hopkins study has shown that patients treated for intracerebral hemorrhage, survived more often if given 1 milligram instead of the previously studied 3 milligram dose of the clot-busting drug tissue plasminogen activator ( tPA; Alteplase
Longer Time Frame for Clot-Busting Drug May Help Beat Stroke: Tissue plasminogen activator (tPA), also known as the drug alteplase, is an approved treatment for the most common kind of stroke -- ischemic stroke -- in which a blood vessel that supplies blood to the brain is blocked by a blood clot. The three-hour post ...
Reportlinker Adds Stroke: Competing Treatments and Market Entry Considerations: This report presents the findings of a global survey on current treatments and prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA). These findings were made following the participation of more than 230 ...
Could thrombolytic approaches in acute stroke benefit from stringent selection criteria?: Thirteen years after the New England Journal of Medicine published a pivotal study from the National Institute of Neurological Disorders and Stroke (NINDS), 1 neurologists universally recognize that the thrombolytic agent alteplase (recombinant tissue ...
Genentech's steady focus on research yields a plump bottom line: Tough times. Early stumbles humbled Genentech, however. In 1987, it predicted sales of Activase, a drug that dissolves blood clots in heart attack victims, would top $1 billion. But the FDA delayed approval of the drug and later found serious side effects.
Few options for stroke victims; research continues: LOS ANGELES (Reuters) - More than a decade after the launch of clot-buster Activase, the Genentech Inc drug remains the only option for stroke victims despite high-profile research aimed at improving the odds of recovery from the No. 3 cause of death in ...
ThromboGenics Rises After Roche Buys Cancer Treatment (Update2): The San Francisco, California-based drugmaker, majority owned by Roche, sells the drug under the name Activase. ThromboGenics will be able to exempt 80 percent of revenue from future royalties of TB-403 from taxes under an effort by Belgium's government to ...
Divergence in function and expression of the NOD26-like intrinsic proteins in plants: © 2009 Liu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and ...

Stroke drug cuts damage even after 3 hours - study: Alteplase, sold under the band name Activase by Genentech DNA.N and Actilyse by privately held Boehringer Ingelheim, is approved as a treatment within three hours after the appearance of stroke symptoms. The new study was designed to see if it reduced ...
Tips from Other Journals: How Long After Acute Ischemic Stroke Is Alteplase Effective? Am Fam Physician. 2009 Sep 1;80(5) Online. Background: Alteplase (Activase) is currently the only approved treatment for acute ischemic stroke. Patients receiving alteplase within three hours ...
Drug market for acute ischemic stroke to reach $450M in 2018: Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of agents to treat acute ischemic stroke will remain relatively flat over the next decade, increasing from $360 million in ...
Aspen hospital taps stroke specialists via new telemedicine hookup: If the patient is treated with the drug, called tissue Plasminogen Activase (tPA for short), he or she will typically be transported to Swedish for follow-up care. “They always say that I look much better over the camera,” Fanale quipped. Strokes are ...
Acute Ischemic Stroke-Drug Pipeline Analysis and Market Forecasts to 2015: GlobalData, the industry analysis specialist's new report, "Acute Ischemic Stroke-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global Acute Ischemic Stroke (AIS) market. The report ...
Inspire Names Dr. Charles Johnson as Executive Vice President of Research and Development and Chief ...: DURHAM, N.C.--( BUSINESS WIRE )--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Executive Employment Agreement with Charles A. Johnson, M.D., who will become Executive Vice President of Research and Development and ...
Vital window for stroke drug: Your account has been frozen . For your available options click the below button. Taking the clot-busting drug alteplase within 90 minutes of a stroke "gives patients more than double the chance of full recovery", said ...
Intrexon Division on the Move: ... acquisition assignments, he played a significant role in the direct financing for the development of the enzyme Ceredase® (the predecessor to Cerezyme®), the recombinant protein Activase®, tissue plasminogen activator, and Protropin®, the ...
Window of opportunity for stroke treatment widens: That left 730 patients, half of whom were then randomly assigned to get infusions of the tPA drug called alteplase. The others received a placebo. After three months, roughly 52 percent of study patients treated with tPA within the extra 90 minute ...
World Stroke Congress 2008: Advances in Stroke Imaging: An Expert ...: ECASS looked at about 800 patients in whom alteplase (tPA) thrombolytic therapy could be started within 3 to 4.5 hours of acute stroke onset. The imaging they used in this trial was very primitive, just a head CT to exclude brain hemorrhage. Patients ...

Want to contact an Activase attorney in District of Columbia?...Get a free case evaluation from one of our Activase attorneys in District of Columbia now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: 1 2 Next

Need An Activase Attorney?

First Name Last Name Email Address State

Legal Issue

FDA Drug Database: Activase Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Activase Information

Click to View Our Legal Resources

Want to contact an Activase attorney in District of Columbia?...Get a free case evaluation from one of our Activase attorneys in District of Columbia now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120522-133529

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

FDA Drug Database: Activase Click to select a Legal Issue

Close (x)

Find Legal Help for Your Activase Case - Submit Your Information Below

Do you need legal assistance with your Activase case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * FDA Drug Database: Activase Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.